PillRx only · Patch, Extended Release · Transdermal
Dextroamphetamine
Brands: Xelstrym · Dextroamphetamine
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US4 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$16.250
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
2.8K
Rx · 2026 Q1
86K
Units dispensed
+71%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Noven Therapeutics, LLC | unknown | 4 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Oct 31, 2024RECALLRecall (Class II): Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30 individually sealed transdermal …
Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive). — Recalling firm: Noven Pharmaceuticals Inc — USA nationwide.